Screener
Kymera Therapeutics KYMR PP&E (Net)
PP&E (Net) at other companies
Other financials
Where this comes from
Reported directly by Kymera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.
The source filing: Kymera Therapeutics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 7:15 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333849
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Prepaid expenses and other current assets | 26,280 | 22,938 |
| Total current assets | $737,265 | $871,214 |
| Marketable securities, non-current (Note 4) | 813,901 | 771,158 |
| Property and equipment, net (Note 6) | 39,971 | 43,175 |
| Right-of-use assets, operating leases | 41,100 | 42,351 |
| Other non-current assets | 7,385 | 9,114 |
| Restricted cash | 5,822 | 5,800 |
| Total assets | $1,645,444 | $1,742,812 |
Item 1. Financial Statements.
FAQ
- What is Kymera Therapeutics's PP&E (net)?
- Kymera Therapeutics (KYMR) reported PP&E (net) of $39.97M in Q2 2026.
- How has Kymera Therapeutics's PP&E (net) changed year-over-year?
- Kymera Therapeutics's PP&E (net) decreased by 17.7% year-over-year, from $48.57M to $39.97M.
- What is the long-term trend for Kymera Therapeutics's PP&E (net)?
- Over 5 years (2020 to 2025), Kymera Therapeutics's PP&E (net) has grown at a 31.8% compound annual growth rate (CAGR), from $10.84M to $43.18M.
- What does PP&E (net) mean?
- Total property, plant, and equipment minus accumulated depreciation — the net book value of all tangible long-lived assets.
Ask your AI about Kymera Therapeutics's pp&e (net).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude